Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

Biological Psychiatry

Volumn 40, Issue 12, 1996, Pages 1298-1300

  Van Berckel, Bart N M ^a   Hijman, Ron ^a   Van Der Linden, Jeroen A ^a   Westenberg, Herman G M ^a   Van Ree, Jan M ^a   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

D cycloserine; glutamate; N methyl D aspartic acid; negative symptoms; schizophrenia

Indexed keywords

CYCLOSERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CYCLOSERINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD;

EID: 0030589547     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00311-3     Document Type: Article

References (12)

1. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994): D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia - An open-label study. J Neural Transm Gen Sect 95:105-111.
2. Goff DC, Tsai GC, Manoach DS, Coyle JT (1995): Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
3. Itil T, Keskiner A, Kiremitci N, Holden JM (1967): Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 12:209-212.
4. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiatry 148:1301-1308.
5. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
6. Kay SR, Fiszbein A, Opler LA (1987): The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
7. Krystal JH, Karper LP, Seibyl JP, et al (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
8. Lahti AC, Koffel B, Laporte D, Tamminga CA (1995): Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
9. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959): Study of a new schizophrenomimetic drug - Sernyl. AMA Arch Neurol Psychiatry 81:363-369.
10. Mandell GL, Petri WAJ (1996): Drugs used in the chemotherapy of tubercuclosis, Mycobacterium avium complex disease, and leprosy. In Goodmann LS, Gillmann A (eds), The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, pp 1164-1165.
11. Olney JW, Farber NB (1995): Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
12. Thompson LT, Moskal JR, Disterhoft JF (1992): Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359:638-641.